Lataa...
Pulmonary large cell carcinoma, highly positive for PD‐L1, shows marked response to pembrolizumab: A case report
Pulmonary large cell carcinoma (LCC) is classified as a poorly defined entity among non‐small cell lung cancers (NSCLCs). At present, there are no effective anticancer drugs, such as molecular targeted drugs, for LCC, and it has been reported that patient prognosis is poor. Recently, the development...
Tallennettuna:
| Julkaisussa: | Thorac Cancer |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons Australia, Ltd
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8017242/ https://ncbi.nlm.nih.gov/pubmed/33605014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13850 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|